Mubadala

Vividion

Vividion was founded in 2016 based on the integration of two foundational technologies out of the Scripps Institute:

Vividion was founded in 2016 based on the integration of two foundational technologies out of the Scripps Institute:

(i) Benjamin’s Cravatt’s proteome-wide whole-cell screening assay; and
(ii) Phil Baran / Jin-Quan Yu’s highly differentiated and tailored chemical library.

The Company has developed a high-throughput screening mass spectroscopy-enabled discovery platform to streamline the drug discovery processes that focus on previously “undruggable” targets.